Personalizing chronotherapy of immune checkpoint blockade

Administering immune checkpoint inhibitors (ICIs) earlier in the day is associated with significantly improved efficacy across all cancer types.

• Time-of-day (ToD) plays a critical role in the efficacy of immunotherapy.
• The circadian system regulates various physiological processes, including immune functions.
• Each individual has a unique chronotype, indicating their natural preference for activity timing.
• Chronotype may serve as a valuable predictor of treatment outcomes in immuno-oncology.
• Current clinical practices for ICI administration are largely time-agnostic, lacking chronotype consideration.
• There is a need for prospective clinical trials to validate chronotype-based scheduling for immunotherapy.

AI simplified